uniQure N.V. QURE

NAS: QURE | ISIN: NL0010696654   14/11/2024
6,750 USD (-0,74%)
(-0,74%)   14/11/2024

5 november 2024 · uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress · Persbericht

15 oktober 2024 · uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS · Persbericht

23 september 2024 · uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease · Persbericht

15 augustus 2024 · uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease · Persbericht

1 augustus 2024 · uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update · Persbericht

23 juli 2024 · uniQure Announces Closing of Sale of Manufacturing Facility to Genezen · Persbericht

9 juli 2024 · uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease · Persbericht

1 juli 2024 · uniQure Announces Sale of Commercial Manufacturing Facility to Genezen · Persbericht

1 juli 2024 · Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA · Persbericht

3 juni 2024 · uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease · Persbericht

7 mei 2024 · uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress · Persbericht

28 februari 2024 · uniQure Announces 2023 Financial Results and Highlights Recent Company Progress · Persbericht

15 januari 2024 · Swissmedic autorise le traitement de thérapie génique HEMGENIX® (etranacogene dezaparvovec) de CSL pour les patients atteints d'hémophilie B · Persbericht

19 december 2023 · uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease · Persbericht

12 december 2023 · CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B · Persbericht

8 december 2023 · uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

29 november 2023 · uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease · Persbericht

7 november 2023 · uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress · Persbericht

27 oktober 2023 · CSL and uniQure Win 2023 Prix Galien USA Award · Persbericht

24 oktober 2023 · uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting · Persbericht

Mijn selecties